SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of November 2009
Commission File Number: 000-31062
(Translation of registrants name into English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted
to furnish a report or other document that the registrant foreign private issuer must furnish and
make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled
or legally organized (the registrants home country), or under the rules of the home country
exchange on which the registrants securities are traded, as long as the report or other document
is not a press release, is not required to be and has not been distributed to the registrants
security holders, and, if discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
This report on Form 6-K and the Underwriting Agreement by and among Oncolytics Biotech Inc.,
Oppenheimer & Co. Inc., and Canaccord Capital Corporation, dated November 18, 2009, attached hereto
as Exhibit 99.1, is hereby incorporated by reference into the Registration Statement on Form F-10
(File No. 333-151513) of Oncolytics Biotech Inc. filed with the United States Securities and
Exchange Commission on June 6, 2008, as amended on June 17, 2008, pursuant to the United States
Securities Act of 1933, as amended.
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
|
99.1
|
|
Underwriting Agreement, dated November 18, 2009 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
Oncolytics Biotech Inc.
(Registrant)
|
|
Date: November 18, 2009 |
By: |
/s/ Doug Ball
|
|
|
|
Doug Ball |
|
|
|
Chief Financial Officer |
|
|